Associação entre os polimorfismos dos genes que codificam a interleucina-6 e a interleucina-10 e qualidade de vida em pacientes com hepatite C crônica

• Ano de defesa: 2018
• Autor(a) principal: Diego Alves Vieira
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; Brasil; MEDICINA - FACULDADE DE MEDICINA; Programa de Pós-Graduação em Ciências Aplicadas à Saúde do Adulto; UFMG
• Palavras-chave em Português: Qualidade de vida; Hepatite C crônica; Transtorno depressivo maior; Interleucina-6,; Interleucina-10; Polimorfismo genético; Citocinas; Hepatite C Crônica; Transtorno Depressivo Maior; Interleucina-6; Qualidade de Vida
• Link de acesso: http://hdl.handle.net/1843/32519

Purpose: Chronic hepatitis C (CHC) has been associated with a decreased health-related quality of life (HRQOL). More recent studies have pointed toward a genetic basis of patient-reported quality of life outcomes. Taking into account that the influence of these SNPs on the HRQOL of patients with CHC has not been studied, we investigated the combined IL10-1082G/A, -819C/T and -592C/A SNPs and IL6-174G/C SNP. We also evaluated the association between demographic, clinical, psychiatric, virological and genetic variables with domains and summaries of HRQOL in CHC patients. Methods: One hundred and thirty-two consecutive CHC patients [72 (54.5%) females; mean age, 52.6 ± 11.4 years] and 98 controls [47 (48.0%) females, mean age; 36.0 ± 10.4 years] underwent psychiatric evaluation by using a Mini International Neuropsychiatric Interview. HRQOL was assessed by a generic questionnaire, the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), and by the specific Liver Disease Quality of Life Questionnaire (LDQOL 1.0). IL6 and IL10 polymorphisms were evaluated by Taqman SNP genotyping assay. Multivariate analysis evaluated the associations. Results: Major depressive disorder was associated with lower SF-36 and LDOQL scores in seven and ten domains, respectively. Diabetes and arterial hypertension were also associated with reduced HRQOL scores. CHC patients carrying the combination of IL10 ATA haplotype and IL6 GG genotype had lower scores in the SF-36 - Physical functioning domain and reduced scores in the LDOQL – effects of liver disease on activities of daily living, quality of social interaction and sexual function domains than the non-carriers of the combined haplotype/genotype. Conclusions: This is the first study to demonstrate that combined IL6 high producer GG genotype and IL10 low producer ATA haplotype are associated with poorer HRQOL in patients with CHC.